PDE3B

Across TCGA pan-cancer cohorts, PDE3B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PDE3B data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher PDE3B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PDE3B expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LSCC, PDAC, and LUAD are the cancer types where PDE3B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	III,IV	1.000	0.343	.011	16	view →
PDAC	OS	Tertile	All	0.325	0.647	.016	8	view →
LUAD	OS	Quartile	All	0.562	0.921	.031	6	view →
HNSC	OS	Tertile	II,III,IV	0.956	0.593	.011	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PDE3B–LSCC (DFS)

Open the LSCC breakdown →